CDMG
NKTR icon

Creek Drive Management Group’s Nektar Therapeutics NKTR Stock Holding History

Creek Drive Management Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$3.6M – 58
2026
Q1 		$3.6M Buy
+50,000
New +$2.85M 0.82% 23

Other funds holding NKTR

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Creek Drive Management Group's NKTR Position: Q2 2026 in Review

Creek Drive Management Group increased its Nektar Therapeutics (NKTR) stake by 92% in Q2 2026, buying an estimated $8.53M and bringing the position to 243,000 shares worth $17M. The position accounts for 8.24% of the portfolio, ranked #3.

Creek Drive Management Group first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Creek Drive Management Group held 243,000 shares of Nektar Therapeutics worth $17M as of Q2 2026.
  • Creek Drive Management Group bought 116,600 Nektar Therapeutics shares in Q2 2026, an estimated $8.53M.
  • Nektar Therapeutics made up 8.24% of Creek Drive Management Group's portfolio in Q2 2026, its #3 holding.
  • Creek Drive Management Group first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Creek Drive Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.